Gastric Cancer: Overexpression of Hypoxia-Inducible Factor 1 as a Prognostic Factor
Despite a worldwide decline in incidence, gastric cancer remains the fourth most common cancer and the second most frequent cause of death from cancer, accounting for 10.4% of cancer deaths worldwide (Parkin, 2004). Though the prognosis of resectable gastric cancer remains fair, the treatment of advanced or recurrent gastric cancer is still far from satisfactory. Currently, the only curative treatment for gastric cancer is a surgical resection of the primary tumor with an appropriate lymphadenectomy because the disease is considered to be resistant to chemotherapy and radiotherapy (Griffiths et al., 2005). Patients with early gastric cancer are in the minority and the disease typically presents at an advanced stage, which often precludes a curative surgical resection. Even in patients who have an apparently curative resection, approximately, a quarter of all individuals tend to progress and develop either recurrent or metastatic disease.
KeywordsOncol Plasminogen Kelly Inositol Parkin
Unable to display preview. Download preview PDF.
- Gray, M.J., Zhang, J., Ellis, L.M., Semenza, G.L., Evans, D.B., Watowich, S.S., and Gallick, G.E. 2005. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 24: 3110–3120.PubMedCrossRefGoogle Scholar
- Griffiths, E.A., Pritchard, S.A., Valentine, H.R., Whitchelo, N., Bishop, P.W., Ebert, M.P., Price, P.M., Welch, I.M., and West, C.M. 2007. Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br. J. Cancer 96: 95–103.PubMedCrossRefGoogle Scholar
- Luwor, R.B., Lu, Y., Li, X., Mendelsohn, J., and Fan, Z. 2005. The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 24: 4433–4441.PubMedCrossRefGoogle Scholar
- Mabjeesh, N.J., Escuin, D., LaVallee, T.M., Pribluda, V.S., Swartz, G.M., Johnson, M.S., Willard, M.T., Zhong, H., Simons, J.W., and Giannakakou, P. 2003. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIE. Cancer Cell 3: 363–375.PubMedCrossRefGoogle Scholar
- Maxwell, P.H., Dachs, G.U., Gleadle, J.M., Nicholls, L.G., Harris, A.L., Stratford, I.J., Hankinson, O., Pugh, C.W., and Ratcliffe, P.J. 1997. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. U.S.A. 94: 8104–8109.PubMedCrossRefGoogle Scholar
- Maxwell, P.H., Wiesener, M.S., Chang, G.-W., Clifford, S.C., Vaux, E.C., Cockman, M.E., Wykoff, C.C., Pugh, C.W., Maher, E.R., and Ratcliffe, P.J. 1999. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271–275.PubMedCrossRefGoogle Scholar
- Talks, K.L., Turley, H., Gatter, K.C., Maxwell, P.H., Pugh, C.W., Ratcliffe, P.J., and Harris, A.L. 2000. The expression and distribution of the hypoxia-inducible factors HIF-1 alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157: 411–421.PubMedGoogle Scholar
- Tan, C., de Noronha, R.G., Roecker, A.J., Pyrzynska, B., Khwaja, F., Zhang, Z., Zhang, H., Teng, Q., Nicholson, A.C., Giannakakou, P., Zhou, W., Olson, J.J., Pereira, M.M., Nicolaou, K.C., and Van Meir, E.G. 2005. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res. 65: 605–612.PubMedGoogle Scholar
- Zagzag, D., Krishnamachary, B., Yee, H., Okuyama, H., Chiriboga, L., Ali, M.A., Melamed, J., and Semenza, G.L. 2005. Stromal cell-derived factor-1 alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res. 65: 6178–6188.PubMedCrossRefGoogle Scholar